Compounding heritable genetic disorders of military toxicant exposure

A developing embryo copies DNA at an extraordinary rate. In the first 8 weeks of pregnancy, a single fertilized egg divides into billions of cells, and each division requires a complete copy of all 3 billion DNA base pairs. Errors during this period are amplified because every daughter cell inherits the mistake. A mutation that hits during week 3, when the neural tube is forming, can produce spina bifida. A mutation during week 5, when limb buds are growing, can produce extra or malformed fingers. A mutation in a tumor-suppressor gene like TSC2 or NF1 can produce tumors that don't appear until childhood or adulthood, because the gene's job is to prevent uncontrolled growth, and that growth goes unchecked once the gene is disabled.

Some birth defects come from the father's damaged sperm rather than from anything that happened during pregnancy. Radiation and alkylating agents (chromium, hydrazine) can mutate DNA in sperm cells years before conception. The child inherits the mutation at the moment of fertilization. This is one way a father's workplace exposure can produce disease in a child who was never near the workplace.

Dioxin adds a third pathway. It can alter the epigenetic tags on sperm DNA without changing the sequence itself. Animal studies showed these altered tags persisting three generations deep: the exposed animal's great-grandchildren still carried the changes despite never being exposed. A grandfather's workplace exposure can affect a grandchild's health even though the grandchild's DNA sequence is normal (Manikkam et al., 2012).

Most safety studies test one chemical at a time. A worker at a nuclear facility or aerospace plant was almost never exposed to just one substance. A typical exposure profile might include ionizing radiation from nuclear materials, hexavalent chromium from metal plating and alloys, ammonium perchlorate from solid rocket propellant, hydrazine from liquid fuel systems, and naturally occurring asbestos in the local geology (common in parts of Southern California, for example).

These substances attack DNA through different mechanisms. Radiation breaks strands. Chromium crosslinks them. Hydrazine mislabels bases. Dioxin reprograms which genes are active. When all of these hit the same cell, the repair systems get overwhelmed. A cell can usually fix a single double-strand break, but not if its mismatch repair machinery is already jammed by chromium crosslinks and its gene regulation has been scrambled by dioxin.

Many of the genetic diseases discussed here — tuberous sclerosis, neurofibromatosis, polycystic kidney disease — follow Knudson's two-hit hypothesis. Every person carries two copies of each gene, one from each parent. A single broken copy is usually survivable because the remaining good copy compensates. Disease manifests only when the second copy is also lost, whether through a new mutation from environmental exposure, radiation damage, or ordinary replication error during cell division. Environmental toxicants that raise the background mutation rate across the genome make loss of that second copy substantially more likely in any given cell over a lifetime.

Hypertension appears in up to 60-70% of adults with ADPKD, often a decade before kidney function declines. The growing cysts compress the blood vessels inside the kidney and activate the renin-angiotensin system, which raises blood pressure. Any adult with polycystic kidneys should have blood pressure monitored regularly, because uncontrolled hypertension accelerates cyst growth and raises the already-elevated risk of intracranial aneurysm rupture.

Aortic and arterial abnormalities are seen in both NF1 (renal artery stenosis, moyamoya-like vasculopathy) and in connective tissue overlap syndromes associated with some of these genetic conditions. NF1 patients have a documented 7-fold increase in cardiovascular mortality compared to the general population (Rasmussen et al., 2001).

Cardiomyopathy from dioxin exposure has been documented in animal studies and in case reports from industrial accidents (Seveso, Italy, 1976). Dioxin activates AhR in cardiac tissue, which disrupts mitochondrial function in heart muscle cells.

Thyroid cancer risk is elevated after ionizing radiation exposure. The thyroid gland concentrates iodine, and when radioactive iodine (I-131, a common fission product) gets into the body, the thyroid absorbs it and receives a concentrated dose. The Chernobyl data showed a 5- to 10-fold increase in thyroid cancer in exposed children (Cardis et al., 2005). Perchlorate exposure paradoxically may be protective against radioiodine (by blocking uptake), but this has not been tested in a combined-exposure scenario.

Autoimmune thyroiditis (Hashimoto's disease) is elevated in populations exposed to radiation and dioxin. The chronic inflammation from either exposure can cause the immune system to attack the thyroid. This compounds the thyroid suppression from perchlorate, creating a double hit on thyroid function.

Pheochromocytoma (adrenal gland tumors that produce adrenaline) occurs in about 1% of NF1 patients. These cause episodes of severe high blood pressure, rapid heartbeat, sweating, and headache. They are treatable if caught, dangerous if missed.

Diabetes risk is elevated in people with chronic inflammation from any cause, and specifically in people with ADPKD (which can involve pancreatic cysts) and in dioxin-exposed populations. The Seveso Women's Health Study found a dose-dependent increase in diabetes risk with dioxin exposure (Consonni et al., 2008).

Hearing loss is the primary presenting symptom of NF2, caused by vestibular schwannomas compressing the hearing nerve. It also occurs in NF1 (from brainstem gliomas or auditory pathway involvement) and as a late effect of radiation exposure and certain chemotherapy drugs (cisplatin in particular). Tinnitus (ringing in the ears) may be the first sign.

Peripheral neuropathy (numbness, tingling, pain in hands and feet) can result from plexiform neurofibromas compressing nerves in NF1, from chemotherapy for brain tumors, from chronic inflammation, and from direct toxic effects of hexavalent chromium and hydrazine on peripheral nerves.

Malignant peripheral nerve sheath tumors (MPNSTs) are the most feared complication of NF1. Plexiform neurofibromas have an 8-13% lifetime risk of malignant transformation. Warning signs include rapid growth of an existing neurofibroma, new pain in a previously painless mass, and change in texture from soft to hard. MPNSTs are aggressive and require immediate surgical evaluation.

Renal cell carcinoma risk is elevated in both ADPKD and in people with chronic kidney inflammation from any cause, including chemical exposure.

Leukemia risk is elevated after ionizing radiation and after exposure to benzene (common in petroleum-based solvents used alongside the other chemicals in aerospace settings). Radiation-induced leukemia has the shortest latency of radiation-related cancers, appearing as early as 2-5 years after exposure.

Breast cancer risk is elevated in women with NF1 (Seminog & Goldacre, 2015, found a 3.5-fold increase) and in radiation-exposed populations, especially those exposed before age 30.

Chronic fatigue is reported at high rates across almost every condition listed in this document. It can result from chronic inflammation, thyroid dysfunction, medication side effects, chronic pain, sleep disruption from headaches (pseudotumor cerebri), sleep apnea (common in NF1 due to airway neurofibromas), or depression. It is often the most disabling symptom that patients report, and it is the one most often dismissed by providers.

PTSD and intergenerational trauma are present in families of veterans and industrial workers who watched their own health decline and then saw their children develop unexplained medical problems. The psychological burden of believing your work caused your child's illness is distinct from the medical burden of the illness itself, and it needs separate treatment.

Everolimus (Afinitor) is FDA-approved for TSC-associated subependymal giant cell astrocytomas (SEGAs), TSC-associated renal angiomyolipomas, and TSC-associated partial-onset seizures. It blocks the mTOR pathway that drives tumor growth in all of these. Side effects include mouth sores, immunosuppression, and impaired wound healing. It does not cure the underlying genetic defect, so tumors regrow if the drug is stopped.

Sirolimus (Rapamune) is the original mTOR inhibitor. It is used off-label for LAM (lymphangioleiomyomatosis) in women with TSC and has been tested in PKD. The RAPTOR trial showed it slowed kidney growth in ADPKD but did not reach statistical significance for GFR preservation at the dose tested.

Tolvaptan (Jynarque) is FDA-approved specifically for ADPKD. It works through a different mechanism (vasopressin receptor blockade, not mTOR) and slows cyst growth by about 50% over three years. It requires regular liver function monitoring because of hepatotoxicity risk. It is expensive (roughly $13,000/month in the US) but most patients access it through manufacturer assistance programs.

Experimental: mTOR inhibitors are being studied for endometriosis in early-phase trials, based on the shared mTOR overactivation in endometriotic tissue and PKD cysts. Search ClinicalTrials.gov for endometriosis + mTOR.

Selumetinib (Koselugo) was FDA-approved in 2020 for children aged 2+ with NF1 who have symptomatic, inoperable plexiform neurofibromas. It blocks the MEK enzyme in the Ras-MAPK pathway that neurofibromin normally controls. In the Phase II trial, 70% of patients had tumor shrinkage of at least 20%. Side effects include skin rash, GI problems, and elevated creatine kinase.

Experimental: MEK inhibitors are being tested in adults with NF1 plexiform neurofibromas (the FDA approval is currently pediatric only), for NF1-associated low-grade gliomas, and for cutaneous neurofibromas (the small skin bumps). The NF Clinical Trials Consortium runs most of these. Search ClinicalTrials.gov for neurofibromatosis + MEK.

NFX-179 is a topical MEK inhibitor being developed specifically for cutaneous neurofibromas (applied as a cream rather than taken orally). Phase II trials are ongoing.

Bevacizumab (Avastin) is used off-label for NF2-associated vestibular schwannomas. It blocks VEGF (vascular endothelial growth factor), which these tumors depend on for blood supply. About 40-50% of patients show tumor shrinkage, and many more have hearing stabilization. It requires IV infusion every 2-3 weeks. Side effects include hypertension, proteinuria, and impaired wound healing.

Bevacizumab has also been used in refractory pseudotumor cerebri (cases that don't respond to acetazolamide and weight loss) based on the role of VEGF in dural venous sinus abnormalities. This use is highly experimental and limited to case reports.

No gene therapy is currently FDA-approved for TSC, NF, or PKD. Several approaches are in development.

For NF1: antisense oligonucleotides and gene replacement strategies are in preclinical work. The Children's Tumor Foundation funds much of this pipeline.

For PKD: CRISPR-based correction of PKD1 mutations has been demonstrated in cell cultures and organoid models. Delivery to enough kidney cells in a living person remains the main obstacle. The PKD Foundation tracks the pipeline at their research page.

For TSC: mRNA-based approaches to restore tuberin (the TSC2 protein) are in preclinical development, drawing on the same mRNA delivery technology used for COVID vaccines.

Search active gene therapy trials: TSC gene therapy | NF gene therapy | PKD gene therapy

Acetazolamide (Diamox) is the first-line drug. It reduces cerebrospinal fluid production. The IIHTT trial (Wall et al., 2014) showed it preserved visual fields when combined with weight loss. Side effects include tingling in the hands and feet, fatigue, kidney stones, and altered taste.

Topiramate (Topamax) is second-line. It also reduces CSF production and has the secondary benefit of promoting weight loss, which is relevant because obesity is a major risk factor for IIH.

Venous sinus stenting is a newer interventional procedure for patients with venous sinus stenosis (narrowing of the veins that drain blood from the brain). A wire mesh stent is placed inside the narrowed vein to hold it open. This reduces brain pressure without drugs. Long-term data is still being collected, but early results are favorable (Dinkin & Patsalides, 2017). Available at specialized neurovascular centers.

Optic nerve sheath fenestration is a surgical option when vision loss is the primary threat. A small window is cut in the membrane around the optic nerve to let fluid drain and reduce pressure on the nerve. It protects vision but does not treat headaches.

Elagolix (Orilissa) and relugolix-estradiol-norethindrone (Myfembree) are FDA-approved GnRH antagonists that suppress estrogen production, shrinking endometrial implants. They cause menopause-like side effects and have time limits on use due to bone density loss.

Laparoscopic excision surgery remains the gold standard for diagnosis and treatment. Excision (cutting out the implants) has better long-term outcomes than ablation (burning). Finding a surgeon trained in excision rather than ablation is important and not always easy. The Nancy's Nook Endometriosis Education site maintains a list of vetted excision surgeons.

Experimental: dichloroacetate (DCA), a metabolic drug, is being tested for endometriosis based on the observation that endometriotic cells have abnormal mitochondrial metabolism similar to cancer cells. Early results from Edinburgh (Horne et al.) are promising. Also watch for mTOR inhibitor trials mentioned above.

Dystrophic scoliosis in NF1 usually requires surgical fusion because bracing is ineffective for this type. Vertebral body tethering (VBT) is a newer, less invasive approach that uses a flexible cord rather than rigid rods, allowing the spine to continue growing. It is available at select pediatric spine centers and works best in patients who are still growing. Not all NF1 scoliosis curves are suitable for VBT; the dystrophic changes in the vertebrae themselves can limit options.

Fetal surgery for myelomeningocele is now available at multiple centers following the MOMS trial (Adzick et al., 2011), which showed that operating on the fetal spine before birth (at 19-25 weeks) reduced the need for shunting by half and improved motor outcomes at 30 months. This is relevant for future pregnancies in families with known exposure-related risk. Centers performing this include CHOP, Vanderbilt, Texas Children's, and UCSF.

Experimental: stem cell patches applied during fetal surgery are in Phase I trials, aiming to regenerate some of the nerve tissue damaged by the open lesion. Search ClinicalTrials.gov for myelomeningocele + stem cell.

What happened. Two water treatment plants serving base housing were contaminated with chlorinated solvents. Tarawa Terrace was contaminated primarily with PCE from an off-base dry cleaner, reaching 215 micrograms per litre, roughly 43 times the current federal limit of 5. Hadnot Point was contaminated primarily with TCE from industrial degreasing, reaching 1,400 micrograms per litre, roughly 280 times the limit. Benzene and vinyl chloride, a breakdown product of TCE, were also present.

When. The 1950s through 1987. The VA presumption covers at least 30 cumulative days of service between August 1953 and December 1987. As many as a million service members, family members and civilian workers were exposed.

Why it matters here. This is the best-characterised exposure on this page for effects in children rather than workers, because ATSDR reconstructed contaminant levels month by month at each residence. Ruckart et al. (2013) studied 12,493 children born between 1968 and 1985 to mothers living on base, and found first-trimester TCE and benzene exposure associated with neural tube defects. PCE and vinyl chloride were associated with childhood cancers. ATSDR additionally lists eye defects, choanal atresia, oral clefts, low birth weight, small for gestational age, fetal death and miscarriage among outcomes with positive findings.

ATSDR Camp Lejeune · VA Camp Lejeune benefits

What happened. A 2,850-acre site in the hills above the San Fernando and Simi Valleys used for rocket engine testing and nuclear research from the late 1940s. It combines almost every exposure on this page in one location: liquid rocket propellant testing (hydrazine and UDMH), solid propellant work (ammonium perchlorate), metal treatment (hexavalent chromium), solvent degreasing (TCE), and ten experimental nuclear reactors. A partial meltdown occurred in the Sodium Reactor Experiment in July 1959. The surrounding geology also contains naturally occurring asbestos.

Why it matters here. SSFL is the clearest real-world example of the combined-exposure problem this document describes. A worker there could accumulate radiation, chromium, hydrazine, perchlorate and solvent exposure across one career, and nearby residents were exposed to airborne and waterborne releases. Almost no published study examines that combination; the site health studies address one agent at a time. Cleanup obligations remain in dispute decades after the site closed.

California DTSC Santa Susana · DOE Santa Susana

What happened. Plutonium production for the Manhattan Project and the Cold War, from 1943. Large atmospheric releases of iodine-131 during the 1940s, including the deliberate December 1949 release known as the Green Run. Radioactive and chemical waste remains stored in ageing underground tanks beside the Columbia River.

Why it matters here. Iodine-131 concentrates in the thyroid, and the thyroid of a fetus or young child concentrates it most. The Hanford Thyroid Disease Study examined outcomes in people exposed as children downwind of the site. Communities in eastern Washington, Oregon and Idaho are often described as downwinders. Thyroid effects connect directly to the endocrine pathway in the diagram above.

Hanford Site · CDC Hanford

What happened. Nuclear weapons plutonium pit production from 1952 to 1989, upwind of the Denver metropolitan area. Major fires in 1957 and 1969 released plutonium. The FBI raided the plant in 1989 over environmental violations, and production never resumed.

Why it matters here. Former workers are covered by the Energy Employees Occupational Illness Compensation Program, and parts of the workforce qualify under a Special Exposure Cohort, which removes the requirement for individual dose reconstruction. Contamination of surrounding land remains contested.

DOE Rocky Flats · EEOICPA

What happened. Atmospheric nuclear testing from 1951 to 1962, then underground testing until 1992. Fallout carried across Nevada, Utah, Arizona and far beyond, depositing iodine-131 onto pasture and into milk supplies.

Why it matters here. The Radiation Exposure Compensation Act provides compensation for downwinders, onsite participants and uranium workers in designated areas and periods, though its coverage and expiry have been repeatedly contested in Congress; check current status before relying on it. The exposure route that mattered most was not direct radiation but iodine-131 through milk, concentrating in children’s thyroids.

DOJ Radiation Exposure Compensation Program · CDC fallout information

Uranium enrichment and processing sites across Tennessee, Kentucky, Ohio and elsewhere exposed workers to uranium, transuranics, solvents and, at several sites, recycled reactor material containing plutonium and neptunium that workers were not told was present.

All are covered by the Energy Employees Occupational Illness Compensation Program, and several have Special Exposure Cohort classes. The DOE Former Worker Medical Screening Program provides free ongoing screening independent of any claim. If a relative worked at any DOE facility, start with the covered facility database rather than trying to reconstruct their exposure yourself.

EEOICPA and covered facilities · Former Worker Screening

What happened. Open-air waste disposal at forward operating bases, burning plastics, electronics, medical waste, munitions and petroleum products, frequently accelerated with jet fuel. Balad Air Base in Iraq operated one of the largest. Burning chlorinated plastics generates dioxins, the same compound class that made Agent Orange harmful.

Coverage. The PACT Act of 2022 established presumptive service connection for service on or after 2 August 1990 in a defined list of South West Asia locations, with further conditions added since. The presumptive list is built around disease in the veteran. Effects in their children are largely unstudied, which is why every burn pit link in the diagram above is graded emerging rather than strong.

VA burn pit exposure · Airborne Hazards and Open Burn Pit Registry

You rarely prove it directly. You establish that a person was in a place, at a time, when that place is documented to have been contaminated. The place does the work.

Military service. Request the full Official Military Personnel File, not the DD-214 alone. The DD-214 is a summary; the personnel file contains duty stations, dates, and military occupational specialty, which is what establishes presence. Use the National Archives SF-180 request. For a deceased relative, the next of kin can request the same file. Ask separately for any exposure or dosimetry records: radiation workers were badged, and those readings were kept.

Civilian nuclear and aerospace work. Employment records, union records, and site industrial hygiene reports. For Department of Energy sites, the Energy Employees Occupational Illness Compensation Program runs its own dose reconstruction, so it does that work for you. Former workers at covered facilities may qualify under a Special Exposure Cohort without individual dose records at all.

Residential exposure. Old addresses matter as much as workplaces. Camp Lejeune claims turn on where a mother lived during pregnancy, because the water system serving each housing area was modelled separately. Base housing records, school enrolment records, and utility records all establish residence.

What to write down now. Every duty station and employer with dates. Every address, with dates. What the parent actually did day to day, in their own words if they are still alive to give them. This is the evidence that is disappearing, and no archive holds it.

Most of these are not ordered unless someone specifically asks. Bring the family history in writing, because a verbal account in a fifteen-minute appointment rarely survives into the chart.

Genetic testing. If two or more of the conditions on this page appear in one person or one sibling group, ask for referral to clinical genetics rather than requesting single-gene tests piecemeal. A geneticist can order a targeted panel (TSC1, TSC2, NF1, NF2, PKD1, PKD2) or whole-exome sequencing, and can interpret a variant of uncertain significance, which a general practitioner usually cannot. Contiguous gene deletions spanning TSC2 and PKD1 need deletion and duplication analysis, not sequencing alone, because sequencing on its own can miss them.

Thyroid. A standard panel measures TSH and sometimes free T4. Ask additionally for thyroid peroxidase and thyroglobulin antibodies, because autoimmune thyroid disease raises miscarriage risk even when hormone levels read as normal. This matters most before and during pregnancy.

Baseline imaging. Brain MRI where there is a phakomatosis or unexplained neurological symptoms. Renal ultrasound where there is any family history of polycystic kidney disease, which detects cysts well before kidney function declines. Ophthalmology including a dilated fundus exam, which detects papilledema and retinal hamartomas that are otherwise invisible.

Blood pressure, seriously. Hypertension appears in most adults with ADPKD a decade before kidney function changes, and controlling it slows the disease. It is the cheapest intervention on this page.

How to get it ordered. Write one page: who was exposed, to what, where, when; which relatives have which diagnoses at what ages; what you are asking for and why. Ask for it to be scanned into the record. A specific written request is far harder to defer than a question asked in conversation.

File an intent to file first. VA Form 21-0966 takes minutes and locks in your effective date for up to a year while you gather evidence. Benefits are backdated to that date, so filing it before you are ready is worth real money.

Check the presumptive lists before doing anything harder. If a condition is presumptive for a given exposure, you do not have to prove that the exposure caused it. You prove service in the right place and time, plus a current diagnosis. That is a fundamentally easier case. Spina bifida in children of Vietnam-era veterans is already presumptive under 38 U.S.C. § 1805, separately from the PACT Act.

If the condition is not presumptive, a claim needs three things: a current diagnosis, evidence of the in-service exposure, and a medical opinion connecting them. That opinion is the nexus letter.

The nexus letter. Written by a physician, it states that the condition is at least as likely as not related to the exposure, and explains the reasoning. That phrase matters: the legal standard is 50 percent, not scientific certainty, and a letter written in the language of scientific certainty can sink a case that should have succeeded. Any physician who knows the patient can write one; it does not have to be a VA doctor. The material in this document, with its citations, is the kind of thing a physician can use to support that reasoning.

Get help, it is free. Accredited Veterans Service Officers file claims at no cost, and they do this daily. Find one through the VA accreditation search, or through a VFW, DAV or American Legion post. Never pay anyone to file an initial claim.

Registries do two things: they connect you to screening and updates, and they build the population data that turns an emerging association into an established one. Several gaps described in this document exist partly because these registries were created late.

VA Airborne Hazards and Open Burn Pit Registry — for post-1990 South West Asia service. Includes an optional in-person evaluation.

ATSDR Camp Lejeune — health studies, notification, and the exposure modelling that underpins the presumptive conditions.

DOE Former Worker Medical Screening Program — free ongoing screening for former Department of Energy site workers, independent of any compensation claim.

Disease-specific registries run by the TSC Alliance, the Children’s Tumor Foundation and the PKD Foundation feed clinical trial matching directly.

Give them the pattern, not the theory. A paediatrician who hears that a grandfather was exposed to Agent Orange and therefore a granddaughter’s scoliosis must be connected will file it under parental anxiety. A paediatrician handed a written family history showing three of these conditions across two generations on both sides will refer to genetics.

What to put on that page: each relative, their diagnoses, and the age at diagnosis. Any occupational or environmental exposure with dates and locations. Any miscarriages or stillbirths, which are frequently left out and are genuinely informative. Do not include your conclusion.

Ask one specific question: does this pattern warrant a genetics referral? That is a question with a yes or no answer, which is much harder to defer than an open-ended concern.

On being dismissed. It happens, often. Chronic fatigue and pain are the symptoms most frequently attributed to anxiety in exactly this population. Asking for a specific test to be documented as declined, with the reason, in the medical record tends to change the conversation, because it converts a judgement call into a recorded decision.

The PACT Act (Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics Act), signed August 2022, is the largest expansion of VA benefits for toxic-exposed veterans in decades. It covers Agent Orange, burn pits, radiation, and other military toxic exposures. It creates presumptive service connections for over 20 conditions, meaning you don't have to prove your specific exposure caused your specific disease, only that you served in the right place and time and have the condition.

VA PACT Act information page

VA Agent Orange benefits and presumptive conditions

VA ionizing radiation exposure benefits

VA hazardous materials exposure (all types)

Spina bifida in children of Vietnam-era veterans is already a presumptive condition under existing VA law (38 U.S.C. § 1805), separate from the PACT Act. Benefits include a monthly monetary allowance and VA healthcare for the affected child.

VA birth defects benefits for children of veterans

If the exposure occurred in a civilian workplace (nuclear plant, aerospace facility, chemical manufacturing), the legal path is usually a toxic tort lawsuit or workers' compensation claim. These cases require documentation of the exposure (employment records, dosimetry badges, industrial hygiene reports) and medical evidence linking the exposure to the disease.

Camp Lejeune Justice Act (part of the PACT Act) specifically covers water contamination at Marine Corps Base Camp Lejeune from the 1950s through 1987. If you or a family member lived or worked at Camp Lejeune during that period, you can file a claim regardless of when the illness appeared.

Camp Lejeune VA benefits page

For Rocketdyne/Santa Susana Field Laboratory (SSFL) exposure specifically, ongoing litigation and cleanup disputes have produced significant case law. The Boeing Company (which acquired Rocketdyne) has faced multiple lawsuits from former workers and surrounding communities.

Finding a lawyer: Look for firms that specialize in toxic tort, environmental exposure, or occupational disease. National firms with track records in this area include:

Baum Hedlund Aristei & Goldman (toxic exposure, including SSFL/Rocketdyne cases)

Simmons Hanly Conroy (asbestos, environmental contamination)

Weitz & Luxenberg (Agent Orange, toxic exposure, mesothelioma)

The DOJ Environment and Natural Resources Division handles federal enforcement actions against polluters. If a government contractor caused the exposure, the Federal Tort Claims Act may apply.

State bar associations maintain referral services for certified specialists in environmental and toxic tort law. Most toxic tort attorneys work on contingency (no fee unless they win).

TSC Alliance provides a financial assistance program, connects patients with clinical trials, and maintains a directory of TSC clinics.

Children's Tumor Foundation (for NF) funds research, maintains a clinical trial registry, and runs the NF Clinic Network with over 60 affiliated centers.

PKD Foundation provides educational resources, clinical trial matching, and connects patients with PKD Centers of Excellence.

Endometriosis Foundation of America provides educational resources and physician directory.

Spina Bifida Association provides healthcare guidelines, clinic directory, and advocacy resources.

Intracranial Hypertension Research Foundation provides patient education for pseudotumor cerebri and connects patients with specialists.

For clinical trial enrollment: ClinicalTrials.gov is the primary registry. Many trials cover travel expenses, provide the drug at no cost, and pay for associated medical monitoring. Ask the trial coordinator about financial support before assuming you can't afford to participate.

Manufacturer patient assistance programs:

Novartis (maker of Afinitor/everolimus): Novartis Patient Assistance

Otsuka (maker of Jynarque/tolvaptan): Otsuka Patient Assistance

Alexion/AstraZeneca (maker of Koselugo/selumetinib): Alexion Patient Services

Genotoxic — capable of damaging DNA. A genotoxic substance may cause cancer, birth defects, or heritable mutations, depending on which cells it damages and when.

Mutagen — a substance that changes the DNA sequence itself. Distinct from a teratogen, which disrupts development without necessarily altering the sequence.

Teratogen — a substance that causes birth defects by interfering with development. Perchlorate acts as a teratogen without being a mutagen: it never touches DNA, it blocks the thyroid hormone the fetus needs.

Epigenetic — affecting which genes are switched on or off, without changing the sequence. Chemical tags sit on top of DNA and control gene activity, and some of those tags are inherited.

Transgenerational inheritance — an effect that persists in descendants who were never themselves exposed. If a pregnant animal is exposed, the fetus and the fetus’s own germ cells are exposed too, so a genuinely transgenerational effect has to be visible in the great-grandchildren before it counts.

Germline versus somatic — a germline mutation is in sperm or egg cells and passes to children. A somatic mutation is in any other cell and does not. Only germline damage is heritable, which is why paternal exposure before conception matters.

mTOR — a signalling pathway controlling cell growth. When the brakes on it fail, cells grow when they should not. TSC, PKD, some brain tumours and endometriosis all involve mTOR running unchecked, which is why one class of drug treats several of them.

Tumour suppressor gene — a gene whose job is preventing uncontrolled growth. TSC1, TSC2, NF1 and NF2 are all tumour suppressors. Losing them removes a brake rather than pressing an accelerator.

Knudson’s two-hit hypothesis — you carry two copies of each gene. One broken copy is usually survivable because the other compensates. Disease appears when the second copy is also lost. Inheriting one broken copy means every cell in the body is one hit away.

Phakomatosis — a group of inherited conditions producing tumours and malformations in tissues derived from the embryonic ectoderm, mainly skin and nervous system. TSC and NF both belong to it.

De novo mutation — a mutation present in a child but in neither parent’s inherited DNA. It arose in a sperm or egg cell, or very early after fertilisation. Environmental mutagens raise the de novo rate.

Double-strand break — both rails of the DNA ladder cut at nearly the same point. Much harder to repair correctly than a single-strand break, and the characteristic damage from ionizing radiation.

Crosslink — a chemical bond that welds DNA to itself or to a protein, jamming the machinery that copies it. The characteristic damage from hexavalent chromium.

Alkylating agent — a substance that sticks small chemical groups onto DNA bases, causing them to mispair when copied. Hydrazine works this way.

AhR, the aryl hydrocarbon receptor — a receptor inside cells that dioxin binds. Once bound, it moves to the nucleus and changes which genes are active. This is how a substance can cause lasting harm without mutating anything.

Sodium-iodide symporter — the transporter that pulls iodine into thyroid cells. Perchlorate blocks it by competing for the same channel.

Presumptive condition — a condition the VA accepts as service-connected without requiring proof that a specific exposure caused it. You establish service in the right place and time, and a current diagnosis.

Nexus letter — a physician’s written opinion that a condition is at least as likely as not related to an exposure. The standard is 50 percent, not scientific certainty.

Dose reconstruction — estimating someone’s historical exposure from records of what was released, where they were, and when, in the absence of personal monitoring data.